Seretide 100, 250, 500 Accuhaler
Last Updated on eMC 12-Jan-2017 View document | GlaxoSmithKline UK Contact details
Versions
- 12-Jan-2017 to Current
- 21-Apr-2015 to 12-Jan-2017
- 20-Apr-2015 to 21-Apr-2015
- 02-Oct-2014 to 20-Apr-2015
- 20-May-2013 to 02-Oct-2014
- 10-Dec-2012 to 20-May-2013
- 22-Dec-2011 to 10-Dec-2012
- 14-Sep-2011 to 22-Dec-2011
- 07-Dec-2009 to 14-Sep-2011
- 14-Jan-2009 to 07-Dec-2009
- 02-May-2008 to 14-Jan-2009
- 24-Feb-2005 to 02-May-2008
- 11-Mar-2004 to 24-Feb-2005
- 31-Jul-2003 to 11-Mar-2004
- 21-Mar-2001 to 31-Jul-2003
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 12-Jan-2017 and displayed until Current
Reasons for adding or updating:
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
- Improved presentation of PIL
Updated on 21-Apr-2015 and displayed until 12-Jan-2017
Reasons for adding or updating:
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 20-Apr-2015 and displayed until 21-Apr-2015
Reasons for adding or updating:
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
- Improved presentation of PIL
Updated on 02-Oct-2014 and displayed until 20-Apr-2015
Reasons for adding or updating:
- Change to section 1 - what the product is used for
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 3 - how to take/use
- Change to section 3 - overdose, missed or forgotten doses
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 5 - how to store
- Change to section 6 - what the product contains
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
- Correction of spelling/typing errors
- Improved presentation of PIL
Updated on 20-May-2013 and displayed until 02-Oct-2014
Reasons for adding or updating:
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 10-Dec-2012 and displayed until 20-May-2013
Reasons for adding or updating:
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 22-Dec-2011 and displayed until 10-Dec-2012
Reasons for adding or updating:
- Change to date of revision
- Change to side-effects
Updated on 14-Sep-2011 and displayed until 22-Dec-2011
Reasons for adding or updating:
- Change to date of revision
- Change to warnings or special precautions for use
- Change to side-effects
Updated on 07-Dec-2009 and displayed until 14-Sep-2011
Reasons for adding or updating:
- Change to drug interactions
Updated on 14-Jan-2009 and displayed until 07-Dec-2009
Reasons for adding or updating:
- Extra statutory information
Updated on 02-May-2008 and displayed until 14-Jan-2009
Reasons for adding or updating:
- Change to date of revision
- Change due to user-testing of patient information
Updated on 24-Feb-2005 and displayed until 02-May-2008
Reasons for adding or updating:
- Change to warnings or special precautions for use
- Change to side-effects
- Change to date of revision
Updated on 11-Mar-2004 and displayed until 24-Feb-2005
Reasons for adding or updating:
- Change to side-effects
Updated on 31-Jul-2003 and displayed until 11-Mar-2004
Reasons for adding or updating:
- Update to PIL
Updated on 21-Mar-2001 and displayed until 31-Jul-2003
Reasons for adding or updating:
- No reasons supplied
GlaxoSmithKline UK
Stockley Park West, Uxbridge, Middlesex, UB11 1BT
+44 (0)208 990 4328
Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Active ingredients
Legal categories
This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue